Literature DB >> 19829080

Downregulation of DeltaNp63alpha in keratinocytes by p14ARF-mediated SUMO-conjugation and degradation.

Maria Vivo1, Antonella Di Costanzo, Paola Fortugno, Alessandra Pollice, Viola Calabrò, Girolama La Mantia.   

Abstract

The tumor suppressor p14(ARF) inhibits cell growth in response to oncogenic stress in a p53-dependent and independent manner. However, new physiologic roles for ARF activation have been proposed. We have previously demonstrated that ARF interacts with p63, influencing its transcriptional activity. p63 is a member of the p53 family involved in skin and limb development, as well as in the homeostasis of mature epidermis. Here, we show that, in human keratinocytes, as well as in tumor-derived cell lines, ARF targets DeltaNp63alpha, the most abundantly expressed p63 isoform, to proteasomal degradation by stimulating its sumoylation. Interestingly, we have observed an increase of ARF expression in differentiating keratinocytes, that is concomitant to the already described upregulation of SUMO2/3. Remarkably, we found that DeltaNp63alpha is preferentially sumoylated by SUMO2, instead of SUMO1, and p14(ARF) increases the efficiency of this process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19829080     DOI: 10.4161/cc.8.21.9954

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  17 in total

Review 1.  p63 in skin development and ectodermal dysplasias.

Authors:  Maranke I Koster
Journal:  J Invest Dermatol       Date:  2010-05-06       Impact factor: 8.551

2.  Ctip2 is a dynamic regulator of epidermal proliferation and differentiation by integrating EGFR and Notch signaling.

Authors:  Ling-juan Zhang; Shreya Bhattacharya; Mark Leid; Gitali Ganguli-Indra; Arup K Indra
Journal:  J Cell Sci       Date:  2012-09-26       Impact factor: 5.285

3.  MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity.

Authors:  Maren H Stindt; Stephanie Carter; Arnaud M Vigneron; Kevin M Ryan; Karen H Vousden
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

4.  PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Authors:  Lisa Ivanschitz; Yuki Takahashi; Florence Jollivet; Olivier Ayrault; Morgane Le Bras; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

5.  Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Authors:  Jackson R Taylor; Brian D Lehmann; William H Chappell; Stephen L Abrams; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2011-08

6.  Bypass of cell cycle arrest induced by transient DNMT1 post-transcriptional silencing triggers aneuploidy in human cells.

Authors:  Viviana Barra; Tiziana Schillaci; Laura Lentini; Giuseppe Costa; Aldo Di Leonardo
Journal:  Cell Div       Date:  2012-02-03       Impact factor: 5.130

7.  Analysis of global sumoylation changes occurring during keratinocyte differentiation.

Authors:  Phillip R Heaton; Andres Santos; Germán Rosas-Acosta; Van G Wilson
Journal:  PLoS One       Date:  2012-01-23       Impact factor: 3.240

8.  MDM2-mediated degradation of p14ARF: a novel mechanism to control ARF levels in cancer cells.

Authors:  Maria Vivo; Maria Matarese; Maria Sepe; Rosaria Di Martino; Luisa Festa; Viola Calabrò; Girolama La Mantia; Alessandra Pollice
Journal:  PLoS One       Date:  2015-02-27       Impact factor: 3.240

9.  Mimicking p14ARF phosphorylation influences its ability to restrain cell proliferation.

Authors:  Maria Vivo; Michela Ranieri; Federica Sansone; Cristina Santoriello; Raffaele A Calogero; Viola Calabrò; Alessandra Pollice; Girolama La Mantia
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

10.  Lactobacillus gasseri SF1183 affects intestinal epithelial cell survival and growth.

Authors:  Blanda Di Luccia; Nicola Manzo; Loredana Baccigalupi; Viola Calabrò; Elvira Crescenzi; Ezio Ricca; Alessandra Pollice
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.